Molecular targeting in acute myeloid leukemia

• Main Authors: Seah H. Lim, Patrycja M. Dubielecka, Vikram M. Raghunathan
• Format: Article
• Language: English
• Published: BMC 2017-08-01
• Series: Journal of Translational Medicine
• Online Access: http://link.springer.com/article/10.1186/s12967-017-1281-x

Abstract Acute myeloid leukemia (AML) is a heterogenous disease associated with distinct genetic and molecular abnormalities. Somatic mutations result in dysregulation of intracellular signaling pathways, epigenetics, and apoptosis of the leukemia cells. Understanding the basis for the dysregulated processes provides the platform for the design of novel targeted therapy for AML patients. The effort to devise new targeted therapy has been helped by recent advances in methods for high-throughput genomic screening and the availability of computer-assisted techniques for the design of novel agents that are predicted to specifically inhibit the mutant molecules involved in these intracellular events. In this review, we will provide the scientific basis for targeting the dysregulated molecular mechanisms and discuss the agents currently being investigated, alone or in combination with chemotherapy, for treating patients with AML. Successes in molecular targeting will ultimately change the treatment paradigm for the disease.